These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38179724)

  • 1. The meaning of non-criteria clinical manifestations in a real-life primary antiphospholipid syndrome cohort.
    Hernández-Molina G; Maldonado-García C; Gamboa-Espíndola M; Cabral AR
    Clin Exp Rheumatol; 2024 May; 42(5):1029-1034. PubMed ID: 38179724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series.
    Madison JA; Gockman K; Hoy C; Tambralli A; Zuo Y; Knight JS
    Pediatr Rheumatol Online J; 2022 Feb; 20(1):17. PubMed ID: 35197077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Serbian Primary Antiphospholipid Syndrome Patients Confirmed a Strong Association Between Livedo Reticularis and Arterial Thrombosis: A National Cross-Sectional Cohort Study.
    Djokovic A; Stojanovich L; Stanisavljevic N; Matic P; Colic D; Skrijelj D; Djokic S; Filipovic B
    J Clin Rheumatol; 2022 Oct; 28(7):362-366. PubMed ID: 35697016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical characteristics of 37 antiphospholipid syndrome patients complicated by autoimmune hemolytic anemia].
    Zhang JT; Qi WT; Zhou YZ; Huang C; Zhao JL; Li MT; Zeng XF
    Zhonghua Nei Ke Za Zhi; 2023 Feb; 62(2):147-155. PubMed ID: 36740405
    [No Abstract]   [Full Text] [Related]  

  • 5. Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study.
    Guédon AF; Catano J; Ricard L; Laurent C; de Moreuil C; Urbanski G; Deriaz S; Gerotziafas G; Elalamy I; Audemard A; Chasset F; Alamowitch S; Sellam J; Maillot F; Boffa JJ; Cohen A; Abisror N; Fain O; Mekinian A
    Arthritis Res Ther; 2022 Jan; 24(1):33. PubMed ID: 35078523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of damage accrual and its impact on health-related quality of life of thrombotic antiphospholipid syndrome: Independent validation of the damage index for antiphospholipid syndrome (DIAPS).
    Gaspar P; Fernandes ASM; Abrantes AM; Parreira I; Silva I; Silva RC; Nobre MB; Martins JR; Mota C
    Lupus; 2024 Jun; 33(7):716-727. PubMed ID: 38616341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature.
    Franco AMM; Medina FMC; Balbi GGM; Levy RA; Signorelli F
    Lupus; 2020 Oct; 29(12):1528-1543. PubMed ID: 32814509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population].
    Marai I; Levi Y; Godard G; Shoenfeld Y
    Harefuah; 2001 Jun; 140(6):495-500, 565. PubMed ID: 11420848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria.
    Demetrio Pablo R; Muñoz P; López-Hoyos M; Calvo V; Riancho L; Martínez-Taboada VM
    Med Clin (Barc); 2017 May; 148(9):394-400. PubMed ID: 28153433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study.
    Hisada R; Kato M; Sugawara E; Fujieda Y; Oku K; Bohgaki T; Amengual O; Yasuda S; Atsumi T
    J Thromb Haemost; 2017 Sep; 15(9):1782-1787. PubMed ID: 28662299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cutaneous manifestations are significantly related to cerebrovascular in a Serbian cohort of patients with Hughes syndrome.
    Stojanovich L; Djokovic A; Stanisavljevic N; Zdravkovic M
    Lupus; 2018 Apr; 27(5):858-863. PubMed ID: 29301476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for arterial thrombosis in antiphospholipid syndrome.
    Matyja-Bednarczyk A; Swadźba J; Iwaniec T; Sanak M; Dziedzina S; Ćmiel A; Musiał J
    Thromb Res; 2014 Feb; 133(2):173-6. PubMed ID: 24321419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors for the Development of the Disease in Antiphospholipid Antibodies Carriers: A Long-term Follow-up Study.
    Pablo RD; Cacho PM; López-Hoyos M; Calvo-Río V; Riancho-Zarrabeitia L; Martínez-Taboada VM
    Clin Rev Allergy Immunol; 2022 Apr; 62(2):354-362. PubMed ID: 34216367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome].
    Moulis G; Delavigne K; Huguet F; Fortenfant F; Beyne-Rauzy O; Adoue D
    Rev Med Interne; 2011 Dec; 32(12):724-9. PubMed ID: 21864953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?
    Gómez-Puerta JA; Martín H; Amigo MC; Aguirre MA; Camps MT; Cuadrado MJ; Hughes GRV; Khamashta MA
    Medicine (Baltimore); 2005 Jul; 84(4):225-230. PubMed ID: 16010207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey.
    Uludağ Ö; Bektaş M; Çene E; Sezer M; Şahinkaya Y; Gül A; Inanç M; Öcal L; Artim-Esen B
    J Thromb Thrombolysis; 2021 Feb; 51(2):466-474. PubMed ID: 32588289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Description of damage in different clusters of patients with antiphospholipid syndrome.
    Uludağ Ö; Çene E; Gurel E; Çetin Ç; Bektaş M; Yalçınkaya Y; Diz-Küçükkaya R; Gül A; Inanç M; Artim-Esen B
    Lupus; 2022 Apr; 31(4):433-442. PubMed ID: 35166607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management.
    Radin M; Ugolini-Lopes MR; Sciascia S; Andrade D
    Semin Arthritis Rheum; 2018 Aug; 48(1):117-120. PubMed ID: 29395258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
    Miyakis S; Lockshin MD; Atsumi T; Branch DW; Brey RL; Cervera R; Derksen RH; DE Groot PG; Koike T; Meroni PL; Reber G; Shoenfeld Y; Tincani A; Vlachoyiannopoulos PG; Krilis SA
    J Thromb Haemost; 2006 Feb; 4(2):295-306. PubMed ID: 16420554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome: aPS/PT antibodies in primary antiphospholipid syndrome.
    Núñez-Álvarez CA; Hernández-Molina G; Bermúdez-Bermejo P; Zamora-Legoff V; Hernández-Ramírez DF; Olivares-Martínez E; Cabral AR
    Thromb Res; 2019 Feb; 174():141-147. PubMed ID: 30612005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.